Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer | Zendy

Naomi Fujioka | Zendy; Julia Nguyen | Zendy; Chunsheng Chen | Zendy; Yunfang Li | Zendy; Teena Pasrija | Zendy; Gloria A. Niehans | Zendy; Katherine Johnson | Zendy; Vinita Gupta | Zendy; Robert A. Kratzke | Zendy; Kalpna Gupta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

Author(s) -

Naomi Fujioka,

Julia Nguyen,

Chunsheng Chen,

Yunfang Li,

Teena Pasrija,

Gloria A. Niehans,

Katherine Johnson,

Vinita Gupta,

Robert A. Kratzke,

Kalpna Gupta

Publication year - 2011

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e318232b35a

Subject(s) - epidermal growth factor receptor , cancer research , epidermal growth factor , protein kinase b , erlotinib , mapk/erk pathway , medicine , signal transduction , biology , microbiology and biotechnology , receptor

Epidermal growth factor receptor (EGFR) is coactivated by the μ-opioid receptor (MOR), expressed on non-small cell lung cancer (NSCLC) cells and human lung cancer. We hypothesized that clinically used opioid analgesics that are MOR agonists coactivate EGFR, resulting in growth- and survival-promoting signaling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research